Context Therapeutics (NASDAQ:CNTX) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Context Therapeutics (NASDAQ:CNTX) issued its quarterly earnings results on Thursday. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01, reports.

Context Therapeutics Stock Performance

NASDAQ CNTX opened at $0.77 on Friday. Context Therapeutics has a one year low of $0.64 and a one year high of $2.75. The stock has a 50-day moving average of $0.85 and a 200 day moving average of $1.44. The company has a market capitalization of $57.88 million, a price-to-earnings ratio of -0.85 and a beta of 2.06.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on CNTX. D. Boral Capital reiterated a “buy” rating and issued a $9.00 price target on shares of Context Therapeutics in a research note on Friday. JMP Securities began coverage on shares of Context Therapeutics in a research note on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $5.00 price target on shares of Context Therapeutics in a research note on Friday. Finally, Citizens Jmp upgraded shares of Context Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 8th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $6.17.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.